At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
Epirubicin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Randomised Phase II to Compare Epirubicin (E) & Cyclophosphamide (C) Treatment Plus Docetaxel (D) & Trastuzumab vs. E & C Treatment Plus D & Lapatinib in Women With Primary Resectable or Locally Advanced HER2+ Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Epirubicin, Cyclophosphamide, and 3 other interventions for Breast Cancer. Completed, enrolled 102 participants across 26 sites.
Detailed Summary
Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib for patients with positive HER2 and resectable or locally advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesSpain
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionDec 2011
Study CompletionDec 2013
TodayJul 2026
First PostedFeb 11, 2009
Enrollment StartFeb 1, 2009
Primary CompletionDec 1, 2011
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 17.4 years ago
Interventions
Epirubicindrug
Cyclophosphamidedrug
Docetaxeldrug
Lapatinibdrug
Trastuzumabdrug